Dynamics of turnover of sugar-lowering drugs in the retail segment of the pharmaceutical market from 2020 to 2024 by D. V. Kurkin, E. V. Makarova, V. I. Zvereva, A. R. Makarova, D. A. Bakulin, O. V. Marincheva, Yu. V. Gorbunova, Yu. A. Kolosov, I. S. Krysanov, K. N. Koryanova, D. A. Galkina, N. A. Osadchenko, R. V. Drai, I. E. Makarenko, A. S. Shuvaeva

Get full text

Original drugs approved by the Food and Drug Administration (Center for Drug Evaluation and Research) in 2024 by D. V. Kurkin, N. A. Osadchenko, A. R. Makarova, D. A. Galkina, D. A. Bakulin, O. V. Shatalova, A. V. Strygin, V. I. Petrov, O. V. Marincheva, Yu. V. Gorbunova, Yu. A. Kolosov, A. V. Zaborovsky, D. V. Yunina, K. N. Koryanova, E. I. Morkovin, M. A. Dzhavakhyan, V. I. Zvereva, R. V. Drai, I. E. Makarenko, A. S. Shuvaeva

Get full text